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The ability of neurons to adapt to environmental 
signals and to memorize novel experiences de-
termines the individual patterns of human and 
animal behavior. In turn, the individual differ-
ences in environmental adaptation and behav-
ior depend on changes in gene expression. The 
fine-tuning of gene expression could be achieved 
at different levels, including regulation by 
microRNAs (miRNAs). miRNAs are small, 
noncoding RNAs that have the ability to nega-
tively control messenger RNA (mRNA) lev-
els or mRNA translation of their target genes 
(He and Hannon, 2004). These miRNA func-
tions are executed by the multiprotein RNA-
induced silencing complex (RISC). At the core 
of RISC are the miRNA-generating enzyme 
Dicer (Hutvágner et al., 2001) and the Argo-
naute (Ago) proteins that bind miRNAs (Lingel 
et al., 2003; Song et al., 2003; Yan et al., 2003) 
and mediate miRNA-dependent mRNA decay 
or translational suppression (Hammond et al., 
2001). The human and mouse genome carry 
four independent Ago genes that encode Ago1, 
2, 3, and 4. The Ago proteins are structurally 
and functionally similar. However, only Ago2 is 
able to control mRNA expression by “slicing” of 
mRNAs that are fully complementary to specific 
miRNAs (Liu et al., 2004; Song et al., 2004).
In addition to its mRNA-regulating function, 
Ago2 contributes to the generation of miRNAs 
from their precursors (Diederichs and Haber, 
2007; O’Carroll et al., 2007). Importantly, this 
poorly understood function of Ago2 appears to 
be selective and affects only a fraction of miRNAs 
within each cell (O’Carroll et al., 2007).
The ability of Ago2 to contribute to the 
generation of specific miRNAs provides an 
opportunity to relate physiological changes 
caused by Ago2 deficiency to expression 
changes of specific miRNAs in various cell 
types, including neurons.
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Cocaine is a highly addictive drug that exerts its effects by increasing the levels of released 
dopamine in the striatum, followed by stable changes in gene transcription, mRNA transla-
tion, and metabolism within medium spiny neurons in the striatum. The multiple changes in 
gene and protein expression associated with cocaine addiction suggest the existence of a 
mechanism that facilitates a coordinated cellular response to cocaine. Here, we provide 
evidence for a key role of miRNAs in cocaine addiction. We show that Argonaute 2 (Ago2), 
which plays an important role in miRNA generation and execution of miRNA-mediated 
gene silencing, is involved in regulation of cocaine addiction. Deficiency of Ago2 in  
dopamine 2 receptor (Drd2)–expressing neurons greatly reduces the motivation to  
self-administer cocaine in mice. We identified a distinct group of miRNAs that is specifically 
regulated by Ago2 in the striatum. Comparison of miRNAs affected by Ago2 deficiency 
with miRNAs that are enriched and/or up-regulated in Drd2-neurons in response to cocaine 
identified a set of miRNAs that are likely to play a role in cocaine addiction.
© 2010 Schaefer et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Deficiency in Ago2 in neurons in the striatum or Drd2-
expressing neurons specifically has no impact on the overall 
morphology of these well-defined brain regions (Fig. 1 B and 
not depicted). Furthermore, as judged by the expression of 
MSN markers such as dopamine- and cAMP-regulated phos-
phoprotein of Mr 32 kD (DARPP-32), the adenosine 2A (A2A) 
receptor, and the dopaminergic neuron marker tyrosine hydrox-
ylase (TH), deficiency in Ago2 has no apparent impact on the 
number, morphology, or distribution of MSNs or their dopa-
minergic innervation in the striatum in vivo (Fig. 1 C). The 
apparent absence of a role for Ago2 in neuronal survival is in 
sharp contrast to the deleterious impact of Dicer deficiency 
in postnatal neurons (Kim et al., 2007; Schaefer et al., 2007). 
Similar to Dicer-deficient cerebellar Purkinje cells (Schaefer 
et al., 2007), postnatal forebrain-specific loss of Dicer (Camk2a-
Cre; Dicerfl/fl; Fig. S1, A–C; Davis et al., 2008), as well as defi-
ciency of Dicer in Drd2-expressing neurons (Drd2-Cre; 
Dicerfl/fl; Fig. S1, D and E), triggers neuronal loss and ensuing 
behavioral abnormalities, followed by the premature death of 
the animals (Fig. S1 and not depicted).
Drd2-specific ablation of Ago2 decreases the motivation  
to self-administer cocaine
The majority of drugs that are abused by humans, includ-
ing cocaine, are also self-administered by animals. Self- 
administration of drugs is generally considered to be the most 
direct measure of the reinforcing properties of a drug, and 
recent studies have shown that mice robustly self-administer 
cocaine (Caine et al., 2002). To investigate the role of Ago2 
and Ago2-dependent miRNAs in the development of cocaine 
addiction, we permitted Drd2-Cre; Ago2fl/fl and Ago2fl/fl control 
mice to self-administer cocaine (0.3 mg/kg/infusion) in their 
home cage environment. The number of cocaine infusions on 
each day over 10 consecutive days was recorded (Fig. 2 A). 
We found that ablation of Ago2 in Drd2-expressing neurons 
leads to a significant decrease of daily cocaine self-administration 
in these mice as compared with controls (Fig. 2 A; F = 24.1, 
P < 0.001). Furthermore, characterization of the cocaine 
dose–response (D–R) curve in each group of mice revealed a 
profound downward shift of the D–R curve in the mutant 
mice (Fig. 2 B; F = 9.1, P = 0.01). Downward shifts in the 
cocaine D–R curve are considered as a decrease in the moti-
vation to consume cocaine (Piazza et al., 2000), supporting 
the notion that the loss of Ago2 in Drd2-expressing neurons 
attenuates the reinforcing effects and thereby leads to a 
decreased motivation to consume the drug. The reduction of 
the reinforcing effects of cocaine as the underlying mecha-
nism for the decreased cocaine intake in those mice is further 
supported by an almost complete lack of preference for an 
environment that the animal was trained to associate with the 
administration of cocaine. Whereas control mice prefer-
entially seek the environment in which they receive cocaine 
over an environment that has been associated with admin-
istration of saline, the conditional place preference to co-
caine is abolished in Drd2-Cre; Ago2fl/fl mice (Fig. 2 C; 
F = 7.76, P = 0.009).
There are >300 miRNAs expressed in the adult mouse 
brain (Lagos-Quintana et al., 2002; Krichevsky et al., 2003; 
Miska et al., 2004). It is very likely that many of these miRNAs 
have highly specialized physiological functions. However, 
identification of these functions in a systematic fashion, e.g., 
by ablating individual miRNAs, is challenging. We argue that, 
by narrowing the number of miRNAs that may contribute to 
specific physiological processes in the brain, one can gain access 
to individual miRNAs that may play a key role in specialized 
adult brain function. Similar approaches have led to the discov-
ery of the essential and unique role of the Ago2-dependent 
miRNA miR-451 in erythropoiesis (O’Carroll et al., 2007; 
Cheloufi et al., 2010; Rasmussen et al., 2010).
We used Ago2 deficiency to address the potential involve-
ment of miRNAs in cocaine addiction. The addictive potential 
of cocaine is related largely to its ability to increase the neu-
rotransmitter dopamine in the striatum. Increased levels of 
released dopamine alter the activity of the dopamine 1 and 
dopamine 2 receptor (Drd1 and Drd2) expressing medium 
spiny neurons (MSNs) in the striatum (Girault and Greengard, 
2004). Administration of cocaine leads to rapid activation and/or 
up-regulation of genes such as Creb1, Fos, FosB, Jun, and 
Cdk5r1, all of which play a role in the formation of cocaine 
addiction (Bibb et al., 2001; McClung and Nestler, 2003; 
Chao and Nestler, 2004; Heiman et al., 2008). Recent data 
suggest that regulation of expression levels of these genes by co-
caine may involve miRNAs (Chandrasekar and Dreyer, 2009).
Here, we show that ablation of Ago2, specifically in mouse 
Drd2-expressing neurons, alleviates cocaine addiction as judged 
by a reduction in the animal’s motivation to self-administer the 
drug. Reduced animal dependence on cocaine is associated with 
selective down-regulation of a specific set of miRNAs in the 
Ago2-deficient striatum. Some of these Ago2-dependent 
miRNAs are present within the pool of the Drd2-enriched 
and cocaine-induced miRNAs. We speculate that this particular 
group of Ago2-dependent, induced by cocaine and Drd2- 
enriched (ADICD) miRNAs plays an important role in cocaine 
addiction. In silico analysis of the putative targets of ADICD 
miRNAs combined with 3 UTR luciferase reporter assays 
highlights their potential involvement in regulation of genes im-
portant for the development of cocaine addiction, such as Cdk5r1 
and the transcription factors FosB and Mef2d. Our studies provide 
evidence for a key role of Ago2 in cocaine addiction and suggest 
ADICD miRNAs as potential regulators of addictive behavior.
RESULTS AND DISCUSSION
Ago2 is dispensable for neuronal survival
Deficiency in Ago2 in specialized adult brain areas has been 
achieved by Cre-mediated recombination of the loxP-modified 
Ago2 alleles (O’Carroll et al., 2007). The expression of Cre re-
combinase in postnatal forebrain neurons or in Drd2-expressing 
neurons has been driven by the neuron-specific Camk2a  
(Casanova et al., 2001) or Drd2 promotors (Gong et al., 2007), 
respectively. Cre-mediated modification of the Ago2 gene 
resulted in the loss of the functional Ago2 alleles and the loss 
of Ago2 protein expression in the striatum (Fig. 1 A).
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Importantly, the absence of Ago2 in Drd2 MSNs in the 
striatum has no apparent effect on various basal behaviors that 
could confound the motivation to self-administer cocaine 
(Fig. 2, D–F, and Fig. S2). The substantial reduction of cocaine 
self-administration reflects neither impaired learning of the 
self-administration task nor a broader alteration of the reward 
response, as Drd2-Cre; Ago2fl/fl mice show no difference in 
responding to food rewards (Fig. 2 D) or in their preference 
for a mild natural reward such as sucrose (Fig. S2 F). More-
over, the Drd2-Cre; Ago2fl/fl and Ago2fl/fl control mice display 
a similar increase in locomotor activity and anxiety after an 
acute injection of cocaine (Fig. 2, E and F), demonstrating 
that loss of Ago2 in Drd2-expressing neurons does not affect 
the sensitivity to the anxiogenic or locomotion-inducing effects 
of acute cocaine, but differentially regulates the motivation to 
consume the drug. Finally, Drd2-Cre; Ago2fl/fl mice show 
normal basal locomotor and exploratory activity and display 
no signs of anxiety or depression-like behavior (Fig. S2, A–E). 
Collectively, these findings indicate that Ago2 and the Ago2-
regulated miRNAs in Drd2-expressing neurons play a crucial 
role in the development of cocaine addiction by regulating 
the motivation to self-administer the drug.
Ago2 regulates miRNA expression in the striatum
In agreement with previously published data (O’Carroll et al., 
2007), we found that Ago2, but none of the other Ago pro-
teins, all of which are ubiquitously expressed in the brain 
(Fig. S3 A), contributes to the generation of a large fraction 
of mature miRNAs. Although the expression levels of over 
94% of miRNAs in the striatum of Ago1/, Ago3/, and 
Ago4/ mice were identical to their expression in the wild-
type striatum, 25% of the analyzed miRNAs (94/376 or 
119/517) in the Ago2 deficient striatum showed a reduction 
in their expression levels (Fig. S3, B and C). More than 85% 
of the down-regulated miRNAs changed their expression 
between 1.5- and 3-fold (relative quantification [RQ] 
value = 0.67–0.34; Fig. 3 A). The magnitude of reduction was 
similar to that found previously in fibroblasts and erythroid 
cells, which revealed a relatively broad, albeit modest, impact 
of Ago2 deficiency on expression levels of affected miRNAs 
(Diederichs and Haber, 2007; O’Carroll et al., 2007). The list 
of down-regulated miRNAs is topped by 15 miRNAs that 
are profoundly affected (3–17-fold reduced expression) in the 
absence of Ago2 in postnatal neurons (Fig. 3 A).
Dependence of miRNA generation on Ago2 appears to be 
biased toward miRNAs originating from the 3p versus the 5p 
hairpin arm of the premiRNAs. Over 70% of Ago2-dependent 
miRNAs that are reduced greater than twofold in the Ago2-
deficient striatum are generated from the 3p arm of their 
corresponding premiRNA (35 out of 49). Furthermore, 
Ago2-dependent, but not Ago2-independent, 3p miRNAs 
display a clear enrichment of miRNAs that have either an 
A or U as the 5 nucleotide in the mature miRNA sequence 
(Fig. 3 B). Recent data showed that miRNAs with either 
an A or U, rather than a G or C, at the 5 position of the 
guide strand of the mature sequence bind with up to 30-fold 
Figure 1. Ago2 is dispensable for brain organization and neuronal 
maintenance in the adult brain. (A) Conditional inactivation of Ago2 in 
adult neurons. Expression of Ago2 was analyzed by Western blotting of 
the striatal protein lysates derived from three Ago2fl/fl mice (lanes 1–3), 
and three Camk2a-Cre; Ago2fl/fl mice (lanes 4–6). The lysates derived from 
Ago2/ and WT mouse embryonic fibroblasts (MEF) were used as con-
trols for the specificity of the anti-Ago2 antibodies. Equal protein concen-
tration in the samples was controlled by  actin loading. (B and C) Ago2 
deficiency in the forebrain does not affect brain morphology. (B) The 
overall brain morphology of 12-wk-old Camk2a-Cre; Ago2fl/fl and Ago2fl/fl 
control mice was analyzed using standard Nissl-stain (n = 3/genotype). 
Two representative images from sagittal brain sections of mice of both 
genotypes are shown. (C) Saggital brain sections of Ago2fl/fl and Camk2a-
Cre; Ago2fl/fl mice are shown (n = 3/genotype). Striatal morphology was 
analyzed by visualizing Drd1 and Drd2 MSNs (top) using antibodies 
against the MSN-enriched protein DARPP-32 (green) and the Drd2- 
MSN–specific adenosine 2A (A2A) receptor (red); the dopaminergic termi-
nals (bottom) were visualized by expression of the dopamine-producing 
enzyme TH (green), and neuronal nuclei in the striatum were visualized by 
using the neuron-specific marker NeuN (red). The nucleus of each cell was 
visualized using Draq5 DNA staining (blue). Bar, 100 µm.
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Acute administration of cocaine leads to an increase 
of 63 miRNAs in Drd2-neurons of wild-type mice (fold 
change > 1.45, P < 0.05; Fig. 4 A). Of those 63 cocaine-induced 
miRNAs, 23 miRNAs are Ago2 dependent (Fig. 4 A).
Ago2-dependent and cocaine-induced miRNAs in Drd2  
cells can control expression of genes essential  
for cocaine addiction
We argue that the contribution of Ago2 to cocaine addiction 
depends on the function of the Ago2-dependent miRNAs. 
In the Drd2 cells, these miRNAs are split between two 
groups. The first group includes Ago2-dependent miRNAs 
that are greatly enriched in Drd2-neurons (Fig. S4 B). The 
second group includes all Ago2-dependent miRNAs that are 
enriched in Drd2 neurons and are induced by acute cocaine 
administration (Fig. 4 A). We speculate that those ADICD 
miRNAs play a role in cocaine addiction. The 23 identified 
ADICD miRNAs (Fig. 4 A) include miRNAs that have a 
potential to control genes that play a crucial role in the devel-
opment of addiction. As an example, in silico predicted targets 
of ADICD miRNAs (using TargetScan 5.0) include cocaine-
induced neuronal plasticity genes such as Creb1 (targeted by 
18/23 Ago2-dependent miRNAs), Fos (3/23), FosB (6/23), 
higher affinity to Ago2 (Frank et al., 2010). We argue that the 
high affinity of 5-A/U–rich miRNAs to Ago2 might con-
tribute to their dependence on Ago2, whereas miRNAs that 
display a low affinity to Ago2 might be “rescued” by other 
Ago proteins.
The majority of miRNAs affected by Ago2 deficiency 
in the striatum are expressed in Drd2 neurons, where they are 
associated with Ago2. Using mice that express transgenic 
FLAG-tagged Ago2 selectively in Drd2 cells (Drd2-Cre; 
Rosa-Stopfl/fl-Flag-Ago2; unpublished data), we found that out 
of 376 well annotated miRNAs, 230 miRNAs are associated 
with the Ago2–RISC complex in Drd2 neurons. (Fig. S4, 
A and B). The spectrum of Ago2-bound miRNAs in Drd2- 
expressing neurons includes almost the entire spectrum of 
Ago2-dependent miRNAs in the striatum of Camk2a-Cre; 
Ago2fl/fl mice (Fig. S4 B). These results further support the 
suggested correlation between miRNA down-regulation in 
response to Ago2 deficiency and miRNA association with the 
Ago2–RISC complex. As an example, the profound reduction 
of miR-431 (which has an U at the 5 position of the mature 
miRNA sequence) in Ago2-deficient neurons (RQ = 0.06; 
Fig. 3 A) correlates with the great enrichment of miR-431 in 
the Drd2-cell expressed Ago2–RISC complex (Fig. S4 B).
Figure 2. Ago2 controls the motivation to self-
administer cocaine in mice. (A) Ago2 controls cocaine 
intake in mice. Cocaine self-administration was measured 
for Drd2-Cre; Ago2fl/fl (n = 12) and Ago2fl/fl control litter-
mates (n = 10). Graph represents the number of cocaine 
infusions (0.3 mg/kg/infusion) earned under a FR5TO20 s 
schedule of reinforcement over 10 consecutive days.  
(B) Ago2 deficiency in Drd2-expressing MSNs results in a 
downward shift in the cocaine D–R curve. The unit dose of 
cocaine available for self-administration was varied  
according to a within-subjects Latin square design  
(0.3 mg/kg/infusion), and the effects of responding to each 
dose of cocaine were assessed in Drd2-Cre; Ago2fl/fl mice 
(n = 12) and Ago2fl/fl controls (n = 10). Data are presented 
as number of cocaine infusions earned on the last day of 
access to each dose of cocaine. (C) Loss of Ago2 in Drd2 
neurons abolishes conditional place preference to cocaine. 
Drd2-Cre; Ago2fl/fl (n = 11) and Ago2fl/fl control (n = 5) 
mice were tested for their preference for an environment 
associated with cocaine versus saline injections and the 
percentage of time (%) spent in the saline or cocaine-
paired side is shown. (D) Ago2 does not control food re-
ward. The response for food reward was assessed in 
Drd2-Cre; Ago2fl/fl (n = 12) and Ago2fl/fl (n = 10) littermate 
controls. Mice responded for food under a FR5TO20 s 
schedule of reinforcement. No differences in operant per-
formance were detected between genotypes. (E and F) 
Ago2 does not control acute cocaine-induced locomotor 
activity (E) or cocaine-induced anxiety (F). Open field anal-
ysis was used to measure locomotor activity and thigmo-
taxis in Drd2-Cre; Ago2fl/fl and Ago2fl/fl control mice  
(n = 8/genotype) at basal level (10 min), followed by 100 µl 
i.p. saline injection (for 10 min), followed by acute cocaine injection (20 mg/kg i.p., 60 min). The bar graphs represent the total distance moved (in centimeters; E)  
and the ratio of total distance moved in the center versus total arena (F). Statistical analysis was performed using a two-way ANOVA (A–D) and a repeated 
measure two-way ANOVA (E and F). Data are shown as means; error bars represent ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 3. Ago2 regulates the expression of miRNAs in striatal neurons. (A) Ago2-dependent miRNAs. The bar graph displays miRNAs that are 
down-regulated in the striatum of Camk2a-Cre; Ago2fl/fl mice as compared with Ago2fl/fl control mice (n = 6/genotype). The miRNAs are ordered  
according to the degree of their down-regulation. (B) Ago2-dependent 3p miRNAs are enriched for A/U at their 5 position. Logo diagrams display all 3p 
Ago2-dependent and 3p Ago2-independent miRNAs in the striatum of Camk2a-Cre; Ago2fl/fl mice as compared with Ago2fl/fl control mice (n = 6/genotype). 
The height of each row corresponds to the sequence conservation at specific positions, and the height of individual letters within a row corresponds to 
the prevalence of that specific nucleotide (nt). Sequences ranging from 30 nt upstream to 48 nt after the first nucleotide of the mature miRNA sequence 
are depicted. The 5-nt of the mature miRNA sequence is located at position 0 (indicated by the beginning of the red bar). 3p miRNAs down-regulated in 
the striatum of Camk2a-Cre; Ago2fl/fl (top) show higher occurrence of A or U at the 5-nt of the mature miRNA than 3p miRNAs that are unaffected by 
the loss of Ago2 (bottom). The table displays the percentage of Ago2-dependent (left) and Ago2–independent (right) 3p miRNAs that have an A/U versus 
a C/G at their 5-position.
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Fosl2 (12/23), Mef2 (3/23), Cdk5r1 (6/23), and Bdnf (11/23), 
all of which play an important role in regulation of cocaine 
addiction (Bibb et al., 2001; McClung and Nestler, 2003; 
Chao and Nestler, 2004; Heiman et al., 2008; Pulipparacharuvil 
et al., 2008). Using a standard 3 UTR luciferase assay, in 
which binding of miRNAs to specific target gene 3 UTRs 
is followed by a reduction of luciferase expression, we were 
able to confirm several of the in silico predicted ADICD 
miRNAs gene targets. As an example, ADICD miRNAs 
miR-369-3p and miR-324-5p can both regulate the expression 
of the neuronal plasticity genes Mef2d and FosB (miR-369-3p) 
or Cdk5r1 (miR-324-5p; Fig. 4 B).
In summary, our studies suggest that the important role of 
Ago2 in cocaine addiction involves the presence or generation 
of specific miRNAs that contribute to the stable changes in 
gene expression patterns that define neuronal cell plasticity 
and ultimately regulate the motivation to consume cocaine. 
We speculate that some or potentially all of the 23 identified 
ADICD miRNAs contribute to cocaine addiction. The current 
findings provide a foundation for future studies that will identify 
the contribution of individual ADICD miRNAs to various 
facets of addictive behavior in mice and possibly humans.
MATERIALS AND METHODS
Generation of neuron-specific Dicer and Ago2 mutant and FLAG-
Ago2 mice
Dicerfl/fl, Ago2fl/fl, Ago1/, Ago3/, and Ago4/ mice were provided by 
A. Tarakhovsky (The Rockefeller University, New York, NY). Dicerfl/fl  
(Yi et al., 2006) and Ago2fl/fl (O’Carroll et al., 2007) mice were bred to Camk2a-
Cre (provided by G. Schuetz, German Cancer Research Center, Heidel-
berg, Germany; Casanova et al., 2001) and Drd2-Cre (Gong et al., 2007) and 
Drd2-eGFP (ER44 line from GENSAT; Heintz, 2004) mice (provided by 
N. Heintz, The Rockefeller University, New York, NY) to generate 
Camk2a-Cre; Dicerfl/fl, Drd2-Cre; Drd2-eGFP; Dicerfl/fl, Camk2a-Cre; Ago2fl/fl, 
Drd2-Cre; Ago2fl/fl, and Dicerfl/fl and Ago2fl/fl control mice. Genotyping was 
performed as previously described (Casanova et al., 2001; Heintz, 2004; 
Yi et al., 2006; Gong et al., 2007; O’Carroll et al., 2007). Transgenic mice 
expressing a Cre-inducible FLAG-HA2-tagged Ago2 under the control of 
the Rosa26 promoter were generated as previously described (Sasaki et al., 
2006; the STOP-eGFP-ROSA26TV vector was a gift from K. Rajewsky, 
Harvard Medical School, Boston, MA). Rosa-Stopfl/fl-Flag-Ago2 mice were 
bred to Drd2-Cre mice to generate mice that express FLAG-HA2-Ago2 
only in Drd2 cells (Drd2-Cre; Rosa-Stopfl/fl-Flag-Ago2). All mice were back-
crossed to the C57BL/6 background for >5 generations. Mice were housed 
under standard laboratory conditions at the Rockefeller University Compar-
ative Bioscience Center. Protocols were approved by the Rockefeller Uni-
versity Institutional Animal Care and Use Committee.
Brain morphology analysis
Brains of 16-d-old Camk2a-Cre; Dicerfl/fl, 8- and 16-wk-old Drd2-Cre; Drd2-
eGFP; Dicerfl/fl, and 12-wk-old Camk2a-Cre; Ago2fl/fl mice and their sex- and 
age-matched littermate controls were perfused and processed as previously 
described (Schaefer et al., 2007). For IHC, sections were incubated with 
anti-GFP (1:5,000; Abcam) and anti-TH (1:500; Millipore) antibodies and 
visualized by the avidin–biotin–peroxidase complex method as described 
(Schaefer et al., 2007). DARPP-32 (1:1,000; Novus Biologicals), NeuN 
(1:1,000; Millipore), TH (1:500; Millipore), and A2A (1:100; Millipore) were 
visualized using immunofluorescence analysis (Alexa Fluor 546/488–labeled 
goat anti–mouse/anti–rabbit IgGs [H+L] dilution 1:500; Invitrogen). Draq5 
(Biostatus Limited) was used to counterstain the nucleus and sections were 
Figure 4. Ago2-dependent miRNAs in Drd2 neurons are induced 
by cocaine and regulate genes involved in cocaine addiction.  
(A) Ago2-regulated miRNAs in Drd2 neurons are induced by cocaine. The 
Venn diagram shows the number of miRNAs that are down-regulated 
(>1.5 fold) in the striatum of Camk2a-Cre; Ago2fl/fl mice (blue;  
n = 6/genotype) and miRNAs that are up-regulated (>1.45-fold) in Drd2 
neurons in response to acute cocaine as compared with saline injections 
(red; n = 3/genotype). The overlapping miRNAs are shown in yellow. The 
bar graph displays all 23 miRNAs that are up-regulated in response to 
acute cocaine in Drd2 neurons (blue bars) and down-regulated in the 
absence of Ago2 in the striatum (red bars). RQ of each miRNA was  
calculated using the Ct method; a maximum standard deviation for 
the Ct values of 0.8 was used as a cut-off for each miRNA. (B) Ago2-
dependent, induced by cocaine and Drd2-enriched (ADICD) miRNAs regu-
late genes important in cocaine addiction. The bar graph displays the 
average percentage of luciferase expression of FosB-, Mef2d-, and 
Cdk5r1- 3 UTR-luciferase vectors in the presence of miR-369-3p,  
miR-324-5p, or a scrambled control as compared with their respective 
vector controls. Each sample was analyzed in triplicates, and three inde-
pendent experiments were performed. Statistical analysis was performed 
using Student’s t test. Error bars indicate + SEM. *, P < 0.05; **, P < 0.01.
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using RQ Manager Software and the Ct method, as recommended. Mouse 
miRNAs that changed >1.5-fold in the mutant samples relative to control 
were assigned as up- or down-regulated (RQ ≥ 1.5 or RQ ≤ 0.667, respectively). 
Calculation of SD was performed according to Applied Biosciences technical lit-
erature as follows: SDCt = (SDtarget2 + SDref2)1/2. A maximum SD of 0.8 was 
allowed for Ct values for all TaqMan Rodent MicroRNA Card applications.
79 nt-long sequences of all 3p miRNAs affected by the loss of Ago2 in the 
striatum of Camk2a-Cre; Ago2fl/fl mice were used to generate Logos using 
WebLogo 2.8.2 (http://weblogo.berkeley.edu/) and compared with all Ago2-
independent 3p miRNAs.
Target validation
Standard 3 UTR luciferase assays were performed to validate in silico tar-
get predictions. 200 ng FosB, Mef2d, or Cdk5r1 3 UTR-luciferase vectors 
(GeneCopoeia) were cotransfected with 20 pmol miRIDIAN mimics 
(Thermo Fisher Scientific) into N2a cells using lipofectamine 2000 (Invitrogen). 
24 h after transfection, cells were lysed and assayed for firefly and renilla 
luciferase expression using the Dual-Luciferase Reporter Assay kit (Promega). 
Following the Promega kit protocol, Victor3V (Wallac 1420) Plate Reader 
(Perkin Elmer) was used to read the absorbance. Each analysis has been done 
in triplicates, and three independent experiments have been performed.
Behavioral analysis
All behavioral tests were performed on 8–24-wk-old mutant mice and their 
respective age and sex matched littermate controls between 9:00 a.m. and 
5:00 p.m. Experiments were conducted by an experimenter blind to the 
genotypes of the mice. GraphPad Prism version 4.03 for Windows (Graph-
Pad Software) was used for statistical analysis of the data. All procedures were 
conducted in strict accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. Cocaine self-administration ex-
periments were conducted at The Scripps Research Institute and approved 
by the Institutional Animal Care and Use Committee.
Locomotor activity in the open field. Locomotion, exploratory, and 
thigmotaxis/anxiety behavior was measured using the open field analysis as 
previously described (Schaefer et al., 2009). For measurements of cocaine- 
induced locomotor and anxiety responses, mice were recorded for 10 min in the 
novel environment, followed by 10 min after sterile saline injection (100 l i.p.) 
and 60 min after injection of 20 mg/kg cocaine i.p. (Sigma-Aldrich; dissolved in 
saline). Open-field data were analyzed using a two-way repeated measure analysis 
of variance (ANOVA) with Bonferoni posttest and Student’s t test.
Light and dark chamber. The light and dark chamber test was used to de-
termine basal anxiety–related behavior. Anxiety-related behavior was mea-
sured by comparing the total time spent in the light using a computer-operated 
Photobeam activity system (AccuScan Instruments). Statistical analysis was 
performed using Student’s t test.
Tail suspension test. Mice were tested for their degree of immobility behav-
ior in the tail suspension test. The Square Test Cubicle (Med Associates, Inc.) 
equipped with a strain gauge was used. The total duration of immobility dur-
ing a single trial of 6 min was calculated as the time the force of the mouse’s 
movements was below a preset threshold. Statistical analysis was performed us-
ing Student’s t test.
Sucrose preference test. Sucrose preference of Drd2-Cre; Ago2fl/fl and 
their sex- and age-matched littermate controls (n = 5 mice/genotype) was 
measured as previously described (Schaefer et al., 2009).
Cocaine place preference. Mice were tested in place conditioning devices 
(Med Associates, Inc.). The experiment consisted of three phases: habitua-
tion (two sessions), conditioning (six sessions), and preference testing (one 
session). During the habituation sessions mice were permitted to freely ex-
plore the apparatus for 30 min to determine whether any mice had an intrin-
sic preference for a particular choice compartment. Mice that spent >70% of 
mounted using Prolong Gold antifade (Invitrogen). Sagittal brain sections 
of 16-d-old Camk2a-Cre; Dicerfl/fl and 12-wk-old Camk2a-Cre; Ago2fl/fl and 
their respective littermate controls were visualized using standard Nissl-stain 
(FD NeuroTechnologies). All brain sections were visualized on a LSM510 
confocal microscope (Carl Zeiss, Inc.) using 10× and 40× (oil) magnifica-
tions. Eight-bit (512X512) images were acquired using LSM software and 
scale bars were added using ImageJ software (National Institutes of Health; 
http://rsb.info.nih.gov/ij).
Taqman real-time RT-PCR analysis
Total RNA was extracted from the striatum of 12-wk-old Camk2a-Cre; 
 Ago2fl/fl, Ago1/, Ago3/, and Ago4/ (O’Carroll et al., 2007) mice and their 
age- and sex-matched littermate controls (n = 2–6/genotype), and mRNA 
quantity and quality were assessed as described previously (Schaefer et al., 2009).
The purified RNA samples were assayed by qRT-PCR for relative 
gene expression using predesigned Taqman gene expression assays from 
Applied Biosystems, as recommended by the manufacture. The following 
TaqMan gene expression assays were used: AGO1 (Mm00462977_m1), AGO2 
(Mm00838341_m1), AGO3 (Mm01188531_mH), AGO4 (Mm01188520_m1), 
and GAPDH (Mm99999915_g1). Relative expression (Ct) and quantifica-
tion (RQ = 2C) for each mRNA were calculated using RQ Manager 
Software, and the Ct method as suggested. Calculation of standard devia-
tion (SDt = [SDtarget2+SDref2]1/2) and error bars (RQ1 = 2^[{Ct + 
SDCt}], and RQ2 = 2^[{Ct  SDCt}]) was performed according to 
Applied Biosystems technical literature part number 4371095 Rev B.
FLAG-Ago2–associated RNA immunoprecipitation  
from Drd2-neurons
The striata of transgenic mice expressing a FLAG-HA2-tagged Ago2 only in 
Drd2 cells (Drd2-Cre; Rosa-Stopfl/fl-Flag-Ago2) were dissected, and Ago2 
cross-linking immunoprecipitation (CLIP) experiments were performed as 
previously described (Chi et al., 2009), with some minor modifications: 30 µl 
magnetic beads precoupled to the M2 FLAG antibody (M8823; Sigma-Aldrich) 
have been used for each immunoprecipitate (IP; 2 striata/IP) after preblocking 
the beads with 2% BSA, 1% t-RNAs, and 1% salmon sperm for 1.5 h at 4°C. 
Immunoprecipitated RNA has been de–cross-linked and purified for 
miRNA qRT-PCR analysis as previously described (Chi et al., 2009) described. 
Enrichment of individual miRNAs in Drd2 neurons were analyzed by com-
parison of Ago2-associated miRNA expression values between Drd2-Cre; 
Rosa-Stopfl/fl-Flag-Ago2 and Rosa-Stopfl/fl-Flag-Ago2 control IPs (n = 4) 
using TaqMan qRT-PCR analysis. miRNAs that showed a greater than two-
fold enrichment (P < 0.05) over control IP in the Drd2-Cre; Rosa-Stopfl/fl-Flag-
Ago2 IP were considered enriched in Drd2 neurons. For identification of 
Ago2-associated miRNAs that are induced by cocaine in Drd2 neurons, 
Drd2-Cre; Rosa-Stopfl/fl-Flag-Ago2 mice were injected with 20 mg/kg cocaine 
or saline (n = 3/genotype) and sacrificed 2 h later. MiRNAs that changed ex-
pression >1.45-fold (SD < 0.8) in acute cocaine versus saline-treated samples 
were considered as induced by acute cocaine in Drd2 cells. TargetScan 
Mouse 5.1 (www.targetscan.org) was used for mouse gene target predictions 
for ADICD miRNAs.
Western blot analysis of immunoprecipitated FLAG-Ago2, IP input, 
and unbound fraction of Drd2-Cre; Rosa-Stopfl/fl-Flag-Ago2 and Rosa-Stopfl/fl-
Flag-Ago2 control mice was performed using NuPage 4–12% Bis-Tris Gels, 
MES running buffer, and SeeBlue Plus2 prestained standard (all Invitrogen) 
following the advanced ECL protocol (GE Healthcare) using Ago2 (ab32381; 
rabbit; 1:1,000; Abcam) and Flag (ab1162; rabbit; 1:1,000; Abcam) anti-
bodies. Membranes were stained before antibody incubation for 5 min in 
Ponceau solution to control for equal protein loading.
miRNA analysis
Total RNA or Ago2-immunoprecipitated RNA was analyzed using TaqMan 
Rodent qRT-PCR analysis (Megaplex MicroRNA Card A and B; Applied 
Biosciences). 10–90 ng of RNA for each sample was reverse transcribed and 
amplified following the ABI Megaplex protocol as recommended (part number 
4399721 Rev. B). Relative expression and RQ for each miRNA were calculated 
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neuronal cell survival in Camk2a-Cre; Dicerfl/fl and Drd2-Cre; Dicerfl/fl mice. 
Fig. S2 shows that the selective ablation of Ago2 in Drd2-expressing 
MSNs has no effect on basal mouse behavior such as locomotion, ex-
ploration, anxiety, mood, and response to a natural reward such as su-
crose. Fig. S3 shows that Ago 1, 2, 3, and 4 are ubiquitously expressed 
in the mouse brain, but that only Ago2 regulates the expression of 
a large group of miRNAs in the striatum. Fig. S4 shows that Ago2- 
dependent miRNAs are associated with the Ago2–RISC complex in Drd2 
neurons and displays the 20 greatest Drd2-enriched and Ago2-dependent 
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